ARTICLE / CLIENT ALERT
SEC Committee Supports Chairman’s Call to Reform Rule 10b5-1 Trading Plans
August 31, 2021
Read time: 4 min
Last week, the US Securities and Exchange Commission’s (SEC) Investor Advisory Committee (IAC) issued recommendations that the SEC impose new restrictions and disclosure requirements for trading plans that afford executives and other insiders the “good faith” defense against allegations of insider trading. The IAC’s actions are expected to add momentum to SEC Chairman Gary Gensler’s recent direction to SEC staff to present recommendations to “freshen up” Exchange Act Rule 10b5-1 by tightening its restrictions.
Rule 10b5-1 was established as a safe harbor to allow an executive or other insider to trade shares in their company according to a written plan adopted while not in possession of material, non-public information without fear of violating insider trading rules—even when trades made pursuant to the plans were executed while the executive or other insider was in possession of material, non-public information. However, the IAC cited research it believes supports concerns that “some plans are used to engage in opportunistic trading behavior that contravenes the intent behind the rule.” Indications that plans have not been used in good faith prompted the IAC to recommend the following:
- A “cooling off” period of at least four months between plan adoption and trading or modification. This would prevent a plan from being adopted in the same quarter that the trades were executed.
- Prohibiting “overlapping plans.” Allowing only one active plan “would signal to the market that a plan was entered into in good faith.”
- Requiring electronic submission of Form 144. Currently, the forms can be mailed to the SEC and are destroyed after 90 days, which the IAC believe makes it more difficult to detect insider trading activities.
- Disclosing in Proxy statements the number of shares scheduled for sale by each of the named executive officers.
- Disclosing on Form 8-K the adoption, modification or cancellation of 10b5-1 plans and the number of shares covered on a timely basis.
- Ensuring that all companies with listed American Depository Receipts (ADRs) and American Depository Shares (ADS) filing Form 20-Fs are subject to Form 4 reporting requirements.
This focus on potential abuse of trading plans coincides with an aggressive enforcement approach to insider trading. For example, the SEC recently employed the novel “shadow trading” theory that possessing confidential information about one company precludes trading in the securities of a competitor. It is fair to say that the SEC is scrutinizing all aspects of insider trading, including potential challenges to the good faith defense under Rule 10b5-1 plans.
The Dodd-Frank Act established the IAC to advise the SEC on regulatory priorities and to promote investor confidence. Its members are drawn from a cross section of the finance, academic and public investor communities. The IAC is expected to formally approve these recommendations at its meeting on September 9, 2021, and its report is replete with more than 30 footnotes to congressional materials, previous proposed rulemaking, academic papers and media reports.
The McDermott Corporate team is equipped to offer assistance to companies contemplating changes to its trading plans or considering submitting comments during the SEC’s impending rulemaking process.

Eighth Circuit Scales Back Equitable Mootness Doctrine for Dismissing Confirmation Appeal
ARTICLE / CLIENT ALERT
Eighth Circuit Scales Back Equitable Mootness Doctrine for Dismissing Confirmation Appeal
August 31, 2021
Read time: 7 min
Courts frequently dismiss creditor appeals of bankruptcy confirmation orders as equitably moot. However, the Eighth Circuit Court of Appeals recently departed from this historic practice. In reversing a District Court determination that confirmation of a plan rendered a creditor’s appeal equitably moot, the Eighth Circuit held that motions to dismiss for equitable mootness should be “rarely granted,” and it reversed and remanded the lower courts’ dismissal of a creditor’s appeal of a Plan Confirmation Order on equitable mootness grounds. With an appellate court taking a strong stand against equitable mootness, other courts will have to examine the issue closely. A circuit split on the issue could end up before the Supreme Court in the coming years. FishDish LLP v. VeroBlue Farms USA Inc., No. 19-3413, No. 19-3487, 2021 WL 3411834 at *7 (8th Cir. Aug. 5, 2021).
Equitable Mootness
Courts apply equitable mootness when they deem a plan “substantially consummated.” This occurs when transactions contemplated by the plan — like issuing new debt and making distributions — have already occurred, and, it would be prejudicial to third parties to “unscramble the egg.” It is an equitable doctrine that, when “limited in scope and cautiously applied,” may prevent substantial harm to numerous parties after confirmation of a bankruptcy plan. However, debtors and parties obtaining superior treatment under a plan often invoke equitable mootness as a strategy to avoid litigating the merits of claims after rushing a plan through confirmation.
Factual Background
FishDish LLP — a preferred shareholder of the fish-farm Debtor companies, VeroBlue Farms USA Inc. and affiliates — appealed the District Court’s order that relied on equitable mootness to dismiss FishDish’s appeal of the Bankruptcy Court’s Plan Confirmation Order. FishDish argued that the Plan violated various provisions of the Bankruptcy Code, including the absolute priority rule, the feasibility requirement and the best interest of creditors test. Alder Aqua — the plan sponsor and sole shareholder of Reorganized Debtors who was slated to assume management — argued that FishDish’s appeal was equitably moot.
In accordance with the Plan, Alder Aqua funded the Plan with $13.5 million dollars, $12 million of which was distributed to creditors. Alder Aqua also agreed to invest $21 million in working capital but deferred making that payment. In addition, all common and preferred stock in the Debtors was cancelled and stock was re-issued to Alder Aqua, which became the sole shareholder. Alder Aqua also assumed management of the Reorganized Debtors and released the Debtors from various claims. Id. at *3.
Analysis
The Eighth Circuit reversed the District Court’s order dismissing the appeal as equitably moot, finding that the District Court made no inquiry into whether the record supported its holding that the Court could not “grant relief without undermining the plan and, thereby, affecting third parties.” Id. at *6 (citing In re SI Restructuring Inc., 542 F.3d 131, 136 (5th Cir. 2008); In re Paige, 584 F.3d 1327, 1337 (10th Cir. 2009)).
The Eighth Circuit agreed with other circuits that the “most important factors are whether the confirmed plan has been substantially consummated and, if so, what effects reversal of the plan would likely have on third parties.” Id. It also cautioned that equitable mootness often results in arbitrary “refusal of the Article III courts to entertain a live appeal over which they indisputably possess statutory jurisdiction and in which meaningful relief can be awarded.” Id. at *1 (citing In re Cont’l Airlines, 91 F.3d 553, 571 (3d Cir. 1996)).
In holding that Article III appellate courts have “a virtually unflagging obligation” to exercise subject matter jurisdiction, the Eighth Circuit concluded that a sufficiently rigorous test must be applied prior to a determination that “bankruptcy equities and pragmatics justify foregoing Article III judicial review of a bankruptcy court order confirming a Chapter 11 plan.” Id. The Eighth Circuit echoed concerns raised by the Third Circuit Court of Appeals in In re One2One Communications LLC, 805 F.3d 428, 446—50 (3rd Cir. 2015), finding that several facts on the record should have given the District Court pause before granting the motion to dismiss.
Specifically, the Eighth Circuit noted that equitable mootness was not intended to protect third-party plan sponsors, like Alder Aqua, and Debtor’s management — especially when the plan sponsor will assume management of the Reorganized Debtors. The Court of Appeals also expressed concern that Alder Aqua’s decision to defer committing working capital — which was the only transfer to not yet occur under the Plan — could have been motivated by a desire to force the Reorganized Debtors to pursue a quick asset sale, rather than resume operations. Finally, the Eighth Circuit held that the District Court could plausibly fashion effective relief for the impaired creditor appellants, even if the business assets had already been sold to a third-party purchaser relying on the confirmed Plan. The Court noted that disgorgement of proceeds is a possible remedy that would not frustrate the Plan’s consummation or the success of the Reorganized Debtors.
The Eighth Circuit held that, on remand, the District Court must make at least a preliminary review of the merits of FishDish’s appeal “to determine the strength of FishDish’s claims, the amount of time that would likely be required to resolve the merits of those claims on an expedited basis, and the equitable remedies available — including possible dismissal — to avoid undermining the plan and thereby harming third parties.” Id. at *7 (emphasis in original).
Takeaways
- The Eighth Circuit joins the Second, Third, Fifth and Tenth Circuits in requiring that District Courts conduct a review of an appeal’s merits to consider whether equitable remedies that avoid undermining the plan and harming good faith purchasers could obviate equitable mootness.
- Creditors should remind courts that issues relating to Article III standing and jurisdiction (such as real mootness) are distinct from equitable mootness doctrine, which involves a court’s unwillingness to alter the outcome of a case — even where a case is not moot and the Court has Article III standing.
- The Eighth Circuit warned that, should equitable mootness become a rule of appellate bankruptcy jurisprudence, rather than an exception, the “Supreme Court, having up to now denied petitions for certiorari to review the doctrine, would likely curtail sharply – perhaps even abolish — its use.”
- While decisions curtailing dismissals of appeals on equitable mootness grounds could benefit creditors by giving them greater leverage, it could also make confirmation more difficult because investors in a post-reorganization company may shy away from the uncertainty created by additional appeals.
Authored by Douglas S. Mintz and Peter J. Amend.
If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2021 Schulte Roth & Zabel LLP.
All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

New Public-Comment Period Regarding Section 301 Tariffs Impacting Certain Medical-Care and COVID-19 Response Products
ARTICLE / CLIENT ALERT
New Public-Comment Period Regarding Section 301 Tariffs Impacting Certain Medical-Care and COVID-19 Response Products
August 30, 2021
Read time: 2 min
As the country continues to experience the effects of the COVID-19 pandemic, the Office of the US Trade Representative (USTR) has invited public comments on whether to continue excluding certain medical supplies from the special tariffs that were originally imposed on imports from China during the Trump administration. Those tariffs, which started in July 2018, followed an investigation conducted under Section 301 of the Trade Act of 1974 of China’s acts, policies and practices related to technology transfer, intellectual property and innovation. The tariffs were imposed on nearly all US imports of Chinese goods, including high-demand medical supplies.
In total, there have been four rounds of tariffs, broadening the scope of affected products. With each round, USTR allowed companies to request exclusions for products that are not adequately available in the United States and granted several of these requests.
Although most of those exclusions have now lapsed, USTR has maintained dozens of product exclusions on medical-care and COVID-19 response products to meet medical needs. On August 27, 2021, USTR published a notice of opportunity to request that these exclusions be extended for up to six months past the current end date of September 30, 2021. Requests must be filed by September 27, 2021 and substantiate the grounds for extending the exclusion.
McDermott’s Trade Group has extensive experience with the Section 301 dispute and its tariff exclusion process, and can assist in filing requests and answering questions.

Mask Up, Vax Up: Illinois Governor Issues Immediate Face Covering Mandate for All, COVID-19 Vaccine Mandate for Healthcare, School and State Workers and Students
ARTICLE / CLIENT ALERT
Mask Up, Vax Up: Illinois Governor Issues Immediate Face Covering Mandate for All, COVID-19 Vaccine Mandate for Healthcare, School and State Workers and Students
August 30, 2021
Read time: 9 min
On August 26, 2021, Illinois Governor J.B. Pritzker issued Executive Order 2021-20 (COVID-19 Executive Order No. 87) (the Order). The Order mandates that all individuals in Illinois who are at least two years old and who are medically able must wear face coverings indoors and in other specified settings. In addition, the Order mandates COVID-19 vaccination for certain professionals in healthcare and education, as well as for students and state employees, subject to certain exemptions which require regular COVID-19 testing. The Order is effective immediately.
FACE COVERING REQUIREMENTS
The Order requires all individuals in Illinois two years old or older, and regardless of vaccination status, to wear a face covering over their nose and mouth when in an indoor public space, so long as they are able to medically tolerate a face covering. Where individuals are in close contact with others in an outdoor setting, the Order also strongly suggests (but does not mandate) wearing a face covering. Face coverings may be removed by (1) individuals actively eating or drinking (including in bars and restaurants), and (2) workers in workplaces when they can consistently maintain six feet of distance (such as when workers are in their office or cubicle space).
In addition to indoor public spaces, the Order confirms that individuals will continue to be required to wear a face covering in the following areas:
- Public transportation and gathering hubs (planes, buses, trains, airports and bus or train stations);
- Congregate facilities (such as correctional facilities and homeless shelters); and
- Any healthcare setting.
COVID-19 VACCINATION REQUIREMENTS
What are the vaccination requirements and deadlines?
The Order requires all Health Care Workers, School Personnel, Higher Education Personnel and Higher Education Students (each as defined below) to (1) receive at least the first dose of a two-dose COVID-19 vaccine series or a single-dose COVID-19 vaccine within 10 days after issuance of the Order (i.e., by September 5, 2021), and (2) be fully vaccinated against COVID-19 within 30 days following administration of their first dose in a two-dose vaccination series.
“Fully vaccinated” means that it is two weeks after receiving the second dose of a two-dose series of a COVID-19 vaccine authorized for emergency use (EUA), licensed or otherwise approved by the US Food and Drug Administration (FDA), or two weeks after receiving a single-dose COVID-19 vaccine authorized for emergency use, licensed or otherwise FDA-approved.
The Order also requires state employees at state-owned or operated congregate facilities to have both doses of a two-dose COVID-19 vaccine series or a single-dose COVID-19 vaccine by no later than October 4, 2021, subject to bargaining.
Who is covered by the Order?
The Order generally applies to all individuals who meet the definition of Health Care Worker, School Personnel, Higher Education Personnel or Higher Education Student, and it also applies to certain state workers. Specifically:
- “Health Care Worker” is any individual who is (1) employed, contracted or volunteering at a healthcare facility (defined below); and (2) in close contact (fewer than six feet) with other persons for 15 or more minutes at least once per week on a regular basis as determined by the healthcare facility. A “Health Care Facility” is broadly defined to include any institution used to provide health services, medical treatment/nursing and rehab or preventative care. This includes the following: ambulatory surgical treatment centers, hospices, hospitals, physician offices, dental offices, free-standing emergency centers, urgent care facilities, birth centers, post-surgical recovery care facilities, end-stage renal disease facilities, long-term care facilities (including skilled and intermediate long-term care facilities licensed under the Nursing Home Care Act, the ID/DD Community Care Act or the MC/DD Act), Specialized Mental Health Rehabilitation Facilities, assisted living facilities, supportive living facilities, medical assistance facilities, mental health centers, outpatient facilities, public health centers, rehabilitation facilities, residential treatment facilities and adult day care centers.
- “School Personnel” means any person (1) employed, contracted or volunteering at a school or school district with student pre-kindergarten through 12th grade, and (2) in close contact (fewer than six feet) with other persons in the school for 15 or more minutes at least once per week on a regular basis as determined by the school. “School” refers to both private and public elementary or secondary school, including charter schools, serving students in pre-kindergarten through 12th grade, including state-operated residential schools.
- “Higher Education Personnel” means any person (1) employed, contracted or volunteering to provide services for an institution of higher education, or employed by an entity contracted to provide services for an institution of higher education, and (2) in close contact (fewer than six feet) with other persons in the school for 15 or more minutes at least once per week on a regular basis. An “Institution of Higher Education” is any publicly or privately operated university, college, community college, junior college, business, technical or vocational school or other educational institution offering degrees, programs or instruction beyond the secondary school level.
- “Higher Education Student” means any individual enrolled in credit-bearing or non-credit bearing coursework at an institution of higher education, either on campus or at an affiliated off-campus location. Importantly, the Order does not apply to students completing their coursework exclusively remotely.
- In addition, the Order’s vaccine mandate applies to all state employees, as well as contractors or vendors, who work at “state-owned or operated congregate facility,” meaning congregate facilities operated by the Illinois Department of Veterans’ Affairs, the Illinois Department of Human Services, the Illinois Department of Corrections and the Illinois Department of Juvenile Justice.
Is anyone excluded from the Order?
Yes. The Order does not apply to:
- Healthcare workers employed, contracted or volunteering for any state-owned or operated facility;
- Students completing their coursework exclusively remotely; and
- Individuals who are present at a covered Health Care Facility, School or Institution of Higher Education or affiliated off-campus location, or contractors or vendors who are present at state-owned or operated congregate facilities, if they are present for only a short period of time and their movements of close proximity to others is fleeting (e.g., contractors making deliveries and who remain physically distanced or individuals who enter a site briefly to pick up a shipment).
Though the Order does not state explicitly, given the exclusion of individuals who are present at covered facilities and locations for only short periods of time, fully remote employees appear to be excluded from the Order, as well.
What types of proof are acceptable to demonstrate COVID-19 vaccination status?
Individuals covered by the Order must provide proof of COVID-19 vaccination to their applicable facility or school. Proof of COVID-19 vaccination may be met by providing any of the following:
- A Centers for Disease Control and Prevention (CDC) COVID-19 vaccination record card or photograph of the card;
- Documentation of vaccination from a health care provider or electronic health record; or
- State immunization records.
Are there any exemptions to the vaccine mandate?
Yes. Individuals are exempt from the Order’s requirement to be fully vaccinated against COVID-19 if they demonstrate that vaccination is medically contraindicated, including any individual who is entitled to accommodation under the Americans with Disabilities Act or other disability-related reasonable accommodation law. An individual is also exempt from vaccination if it would require the individual to violate or forego a sincerely held religious belief, practice or observance. (The Order is silent on any further procedures for furnishing proof of exempt status.)
The Order further provides that covered individuals who are not fully vaccinated against COVID-19 must be excluded from the premises unless they comply with the testing requirements set forth in the Order. It is unclear whether the testing option is available to anyone who chooses not to receive a COVID-19 vaccination, or whether it may only be available for those individuals with an approved medical or religious exemption or who are in process to become fully vaccinated at the time the Order becomes effective.
Are there additional safety requirements that apply to anyone who is not fully vaccinated?
Yes. Starting 10 days after the Order’s issuance, on September 5, 2021, any Health Care Worker, School Personnel, Higher Education Personnel or Higher Education Student who is not fully vaccinated must be excluded from the premises of the applicable Health Care Facility, School or Institution of Higher Education unless the individual is tested for COVID-19 at least weekly with a test that has EUA or is operating per the Laboratory Developed Test requirements by the CDC.
The Health Care Facility, School or Institution of Higher Education must either conduct the testing on site, or must obtain proof or confirmation from the individual of a negative test result obtained elsewhere. Though not required, the Illinois Department of Public Health recommends that PCR tests are used for this testing, if available.
State employees who are covered by the Order and who are exempt from vaccination pursuant to medical or religious reason will also be required to comply with additional testing requirements; however, the Order is silent on the details of such requirements as to state employees, possibly due to bargaining obligations.
Are Illinois employers permitted to implement their own vaccination requirements, even if the Order does not require them to do so? And can covered facilities implement more stringent requirements than the Order requires?
The Order explicitly states that nothing in the Order shall prohibit any entity from implementing its own vaccination and/or testing requirements for personnel, contractors, students or other visitors that exceed the requirements of the Order. Moreover, the Order encourages all entities to implement robust vaccination and testing programs to reduce the spread of COVID-19.

Distressed M&A: Is the Wave Still Coming?
ARTICLE
Distressed M&A: Is the Wave Still Coming?
August 26, 2021
Read time: 2 min
In the wake of the corona pandemic, numerous M&A transactions were halted due to economic challenges and uncertainties in the target companies’ business models. While the M&A market has quickly returned to old form in many areas, the wave of distressed deals has so far failed to materialize despite all the challenges. Is it still coming? By Norman Wasse and Dr. Michael Cziesla.
Mergers & Acquisitions Laws and Regulations 2021, Germany
ARTICLE
Mergers & Acquisitions Laws and Regulations 2021, Germany
August 26, 2021
Read time: 2 min
In this Chapter Norman Wasse and Lisa Schickling provide an overview of the M&A market in Germany in 2020, using transaction volumes and the largest deals to highlight the relevant practical legal developments.

Illinois Enacts New Noncompete and Nonsolicit Law
ARTICLE / CLIENT ALERT
Illinois Enacts New Noncompete and Nonsolicit Law
August 25, 2021
Read time: 7 min
Illinois has enacted a new law governing restrictive covenants: Public Act 102-0358. This law outlines the requirements for valid noncompetition and nonsolicitation agreements, and enforcement of those covenants. It will apply to all agreements entered into on or after January 1, 2022.
EXECUTIVE SUMMARY
- This legislation allows an employee to recover costs and reasonable attorney’s fees if the employee prevails in an action seeking to enforce a noncompetition or nonsolicitation agreement.
- Subject to certain carve-outs, this legislation sets income thresholds for noncompetition agreement and nonsolicitation agreements: the employee must earn more than $75,000 per year to be bound by a noncompete and more than $45,000 per year to be bound by a nonsolicit.
- The legislation requires that employers advise employees, in writing, to consult with counsel before entering into a noncompetition or nonsolicitation agreement, and that employees be afforded 14 days to review the covenant before signing.
- The legislation sets adequate consideration for a noncompetition agreement or nonsolicitation agreement: two years of employment or a period of employment plus other professional or financial benefits. Employers will need to consider what additional professional or financial benefits they will offer as consideration beyond simple at-will employment.
- The legislation outlines what legitimate interests support a covenant, but it provides judicial leeway to determine the reasonableness and enforceability of a covenant.
- The legislation discourages, but does not absolutely prohibit, judicial reformation of restrictions—“blue penciling.”
PRACTICAL IMPLICATIONS
This legislation imposes potentially significant costs for employers by including a fee-shifting provision. That, plus the disapproval of blue penciling, is meant to encourage employers to ask for limited restrictions in the first instance.
While many provisions—such as the notice provision—are easy to follow, it is likely that employers will face disparate outcomes on the reasonableness of their restrictions. With few bright line rules, the legislation allows significant leeway to courts in determining the validity and enforceability of agreements.
This combination presents risks for employers who want to be able to enforce their agreements. Employers, therefore, should consult with counsel before implementing any noncompetition or nonsolicitation agreements after January 1, 2022, for new or current employees.
WHAT IS COVERED?
This legislation applies to noncompetition agreements and nonsolicitation agreements entered into after January 1, 2022. It defines each as follows:
- A covenant not to compete is an agreement between an employer and employee that restricts the employee from (1) performing any work for another employer for a specified period of time; (2) performing any work in a specified geographical area; or (3) performing work for another employer that is similar to the employee’s work with the employer that the agreement is with. A covenant not to compete also includes an agreement that imposes adverse financial consequences to the employee for engaging in competitive activities after the termination of employment, such as a bonus clawback provision.
- A covenant not to solicit is an agreement between an employer and employee that restricts the employee from (1) soliciting for employment the employer’s employees, or (2) soliciting (for the purposes of selling products or services of any kind) or interfering with the employer’s relationships with clients, vendors and suppliers (or prospective clients, vendors and suppliers).
Exempted from these definitions are the following: (1) confidentiality agreements; (2) agreements governing the disclosure of trade secrets or inventions; (3) invention assignments; (4) covenants not to compete associated with the sale of a business or business interest; (5) clauses requiring notice before termination, so long as the employee is employed by the employer and paid by the employer during the notice period; and (6) agreements to not reapply for employment with the employer after termination.
WHAT MAKES A COVENANT VALID AND ENFORCEABLE?
There are five factors governing the enforceability of a noncompetition agreement or nonsolicitation agreement:
- The employee must receive adequate consideration. There is adequate consideration if (a) the employee worked for the employer for at least two years after the employee signed the agreement, or (b) the employer provided the employee with a period of employment as well as additional professional or financial benefits.
- The covenant must be tied to a valid employment relationship.
- The covenant is no greater than required for the protection of a legitimate business interest of the employer. This is determined by the totality of the circumstances of the individual case, including (a) the employee’s exposure to the employer’s customer relationships or employees; (b) the near-permanence of customer relationship; (c) the employee’s knowledge or use of confidential information; (d) the length of the restriction; (e) the geography of the restriction; and (f) the scope of the restriction.
- The covenant does not impose an undue hardship on the employee.
- The covenant is not injurious to the public.
Importantly, the legislation does not define what additional “professional or financial benefits” will constitute adequate consideration. Employers will need to consider offering additional consideration beyond at-will employment—e.g., a sign-on bonus, equity grant, year-end bonus, etc.—or risk having an unenforceable restriction if the employee leaves after working less than two years.
The legislation also explicitly asks for individualized consideration of the above factors, noting that what is reasonable for a contract in some circumstances may be unreasonable for the same contract in other circumstances.
Additionally, to be enforceable, the employer must give the employee adequate notice of the agreement. This means advising the employee, in writing, that they should consult with an attorney before entering in the agreement. It also means that the employee must be given 14 days to review the agreement and sign it, though it may be signed earlier at the employee’s election.
WHAT IS ABSOLUTELY PROHIBITED?
This legislation does include a few bright-line rules, setting the following absolute prohibitions:
- Employers cannot enter into covenants not to compete with employees whose annualized rate of earnings are less than $75,000 a year. Likewise, there cannot be nonsolicitation agreements for employees whose annualized rate of earnings are less than $45,000. There are escalators in these thresholds every five years. Earnings includes all forms of taxable compensation reflected on a W-2, including bonus, commissions, tips and employer contributions to benefits plans.
- Employers cannot enter into noncompetition agreements or nonsolicitation agreements with employees who were terminated, furloughed or laid off as a result of business circumstances related to the COVID-19 pandemic or a similar pandemic unless the covenant pays the employee certain additional compensation.
- Employers cannot enter into noncompetition agreements with individuals covered under the Illinois Public Labor Relations Act or Illinois Educational Labor Relations Act.
- Employers cannot enter into noncompetition agreements with construction workers unless those construction workers perform management, engineering, architectural, design or sales functions, or those construction workers are shareholders or partners of the employer.
ENFORCEMENT AND REMEDIES
The legislation encourages employees to impose limited restrictions by including a fee-shifting provision. If an employee prevails on an enforcement action, the employee can recover all costs and all reasonable attorney’s fees for that action.
The legislation reinforces this by limiting blue-penciling—a practice where courts can revise agreements to comply with what is deemed reasonable—because the availability of unlimited blue penciling encourages broad provisions that can be whittled down but still enforced. Courts have limited discretion to blue pencil; they may do so if the original constraints were fair as written and reflected a good faith effort to establish reasonable restrictions. Blue penciling also may be available by explicit agreement by the parties.
The legislation does allow for enforcement by the State Attorney General where there is reasonable cause to believe that a person or entity is engaged in a pattern or practice prohibited by the legislation. The legislation outlines certain procedures for that enforcement, and it permits civil penalties.

The Private Equity Market in Italy: Past, Present and Future
ARTICLE / CLIENT ALERT
The Private Equity Market in Italy: Past, Present and Future
August 25, 2021
Read time: 4 min
Past: Once Upon a Time
Thinking back to pre-pandemic times, it cannot be said that the Italian private equity (PE) and venture capital (VC) market was particularly flourishing or on the rise. Funding was decreasing compared to the trend of previous years, and the volume of investments reached a certain significance (totaling almost EUR 10 billion allocated to almost 450 companies) only if we also take into account any co-investors (not classifiable as PE and VC players), the financial leverage used for buyouts, and the activity of other parties (such as club deals, family offices, special purpose acquisition companies, asset managers and other investment vehicles) that invested alongside traditional investors.
The widespread impression among industry stakeholders, however, was not that the market was facing a contraction or was particularly hectic, but rather was simply tied too closely to the completion of few important transactions rather than following a regular trend.
Present: Loading, Please Wait
Following the H1 2020 setback due to government restrictions, funds have tended to focus on investments in more defensive and resilient sectors (such as technology, energy, pharmaceuticals, healthcare and agribusiness) and on the management and protection of portfolio companies. Consolidation processes (e.g., through add-ons to investee companies) and general injections of liquidity are all the rage. The amount invested is growing steadily.
Today, the time required to close deals has lengthened, and more sophisticated due diligence processes have been introduced, often with a focus on operations. Since the impact of the health emergency on companies has inevitably led to a contraction in margins (in terms of EBITDA) and an increase in debt impacting on capital strength, PE funds are looking with interest at the possibility of seizing an opportunity from this situation, using investment structures that are more complex than in the past (e.g., providing for minorities and for commitments with debt and semi-equity instruments), postponing the process of divestment and trusting in the recovery.
Future: Where to Put My Two Cents
By the end of H1 2021, we gradually began to glimpse a positive market outlook: the number of deals is sharply increasing. Leveraged buyouts and replacement transactions are becoming fashionable once again, mainly in the manufacturing, life sciences and healthcare, and IT sectors.
We are witnessing a significant increase in the size of investments (in particular with regard to transactions above EUR 100 million), yet with lower utilisation of equity for the financing (confirming the trend of involving commercial banks mainly through senior debt) and with little price divergence among sellers and acquirers (an adjustment price clause seems to be mandatory nowadays).
The market seems to be influenced by disruptive trends (e.g., online sales and tech innovations), especially in light of factors such as the spread of remote working, the return to the “green” agenda (which had been temporarily set aside) and the transition towards digital payment methods.
Trade journals and market players seem to be very confident about the growing trend. It remains to be seen whether the above-mentioned disruptive trends will be able to suit the needs of the market, or whether the market will inevitably be revolutionised by a new way of experiencing relationships and, consequently, business.
International Private Equity Market (IPEM) 2021 | Paris Edition
We’re delighted to be attending IPEM 2021, where private equity industry professionals will look ahead to how Europe’s economy will build back post-COVID 19.

Need a Do-Over? IRS Expands and Updates Qualified Plans Correction Guidance
ARTICLE / CLIENT ALERT
Need a Do-Over? IRS Expands and Updates Qualified Plans Correction Guidance
August 24, 2021
Read time: 7 min
The Internal Revenue Service (IRS) issued Revenue Procedure 2021-30, which provides an updated version of the Employee Plans Compliance Resolution System (EPCRS). EPCRS is the IRS’s comprehensive program for plan sponsors to correct tax-qualified plan errors. This EPCRS update expands plan sponsors’ ability and methods to correct overpayments and to self-correct certain plan failures without filing a Voluntary Compliance Program (VCP) application, which can be costly and time-consuming. However, the IRS also eliminated the ability of plan sponsors to submit an anonymous VCP application, replacing anonymous VCP submissions with a pre-submission conference option. A summary of the most significant changes is below. The changes are generally effective July 16, 2021, except as otherwise provided.
INCREASED PLAN SPONSOR FLEXIBILITY FOR CORRECTION OF OVERPAYMENTS
One of the most vexing problems for plan sponsors is how to recoup or correct for overpayments to participants and beneficiaries. In recent years, the IRS has given plan sponsors more flexibility for the correction of overpayments, moving away from the broad requirement that plan sponsors must always seek to recoup repayments from participants and beneficiaries. In the new EPCRS, the IRS further expands plan sponsor options with respect to overpayments as follows:
- The “de minimis” amount under which a plan sponsor is required to correct an overpayment (or report the amount as ineligible for a rollover) is increased from $100 to $250. The de minimis increase also applies to the correction of excess amounts that do not exceed a statutory limit.
- Plan sponsors may now permit overpayment recipients to make repayments through an installment agreement, in addition to the option for a single sum payment.
- For defined benefit plans, plan sponsors may now correct overpayments via two new correction methods that reduce the burden on plan sponsors to repay amounts to the plan:
- 1. The Funding Exception Correction Method. If the plan’s adjusted funding target attainment percentage (AFTAP) is at least 100% on the correction date, no corrective repayments from the participant, beneficiary or plan sponsor are required. However, future benefit payments to the recipient(s) must be reduced to correct the benefit payment amount, and the recipient(s) must be notified that the overpayment amount is not eligible for rollover.
- 2. The Credit Contribution Method. A plan sponsor may reduce the amount required to be repaid to the plan (i) by the cumulative increase in the plan’s minimum funding requirements attributable to the overpayments from the plan year for which the overpayments are taken into account through the end of the plan year preceding the year of correction, or (ii) in certain circumstances by additional contributions paid to the plan in excess of minimum funding requirements after the first overpayment was made. However, future benefit payments to the recipient(s) must be reduced to correct the benefit payment amount. As with the Funding Exception Correction Method, no further corrective action is required, including any payments from the participant, beneficiary or plan sponsor.
ELIMINATION OF THE ANONYMOUS VCP SUBMISSION AND ADDITION OF THE PRE-SUBMISSION CONFERENCE
Under prior versions of the EPCRS, plan sponsors could make anonymous VCP submissions. This allowed plan sponsors to seek IRS approval of corrections for unusual or complex issues—for which there may be uncertainty about a proposed correction method—before providing identifying information about the plan and the plan sponsor. Beginning January 1, 2022, however, the IRS will no longer accept VCP submissions on an anonymous basis and will require identifying information—along with all applicable forms, documents and exhibits—be included with a VCP submission.
Instead, beginning January 1, 2022, the IRS will permit a plan sponsor’s representative to request an anonymous pre-submission conference with the IRS to discuss a plan sponsor’s eligibly for submission under the VCP and proposed corrective actions. The pre-submission conference serves a similar purpose by allowing a plan sponsor to discuss a proposed course of action to correct plan errors before submitting an application. A pre-submission conference may only be requested for matters that are eligible for correction under the VCP and that do not fall into the safe harbor correction methods outlined in the EPCRS appendices. Further, plan sponsor must be eligible and intend to submit a VCP application. There is no cost for this conference, but the plan sponsor’s representative must provide certain required information regarding the applicable failure and proposed correction via the Pay.gov website on Form 8950. The IRS has discretion whether to hold a pre-submission conference.
SELF-CORRECTION PERIOD EXTENDED TO THREE YEARS FOR SIGNIFICANT FAILURES
Plan sponsors have a limited period of time to self-correct “significant” operational and plan document failures using the Self-Correction Program (SCP). In the new EPCRS, the IRS extended this SCP eligibility period from the last day of the second plan year until the last day of the third plan year following the plan year in which the failure occurred. This, in turn, also expands plan sponsor eligibility to correct failures relating to employees’ elective deferrals that last for more than three months, but not longer than the SCP eligibility period described above.
SELF-CORRECTION BY RETROACTIVE PLAN AMENDMENT MADE EASIER
Under EPCRS, a plan sponsor can correct an operational failure through a retroactive plan amendment that conforms plan terms to plan operations in certain circumstances. EPCRS previously allowed such retroactive amendments only if the plan amendment met the following three requirements:
- The amendment resulted in an increase of a benefit, right or feature;
- The increase in the benefit, right or feature applied to all eligible participants; and
- The increase in the benefit, right or feature is permitted under the Internal Revenue Code and otherwise complies with the rules of the EPCRS.
The new EPCRS removes the second requirement—that the increase in the benefit, right or feature applies to all participants—which is often the most difficult requirement to meet. This requirement’s removal expands the ability of plan sponsors to utilize retroactive plan amendment as a self-correction method for many operational failures.
EXTENDED SUNSET OF SAFE HARBOR SELF-CORRECTION OF AUTOMATIC DEFERRAL FAILURES
Plan sponsors may utilize a safe harbor correction method for employees’ elective deferral failures related to automatic contribution features in 401(k) plans. Previously, this safe harbor correction method was expected to sunset on December 31, 2020. However, the IRS extended this sunset period until December 31, 2023.
FINAL THOUGHTS
The IRS continues to take steps to try to help facilitate plan sponsor corrections of administrative and documentary errors in qualified plans. As with previous updates to the EPCRS, these changes should help reduce the cost and burden of common plan failure corrections, and they will provide welcome relief for many plan sponsors with respect to operational plan failures. Plan sponsors should work closely with counsel and their advisors to determine appropriate steps for the correction of plan administrative and documentary errors that occur from time-to-time.

Patents and Trade Secrets Aren’t Mutually Exclusive: The Nuanced Nature of Trade Secret Protection
ARTICLE
Patents and trade secrets aren’t mutually exclusive: The nuanced nature of trade secret protection
August 19, 2021
Read time: 14 min
Addressing the nuanced nature of trade secret protection of patented products, the US Court of Appeals for the Seventh Circuit affirmed a district court’s trade secret protection determination, finding that the asserted trade secrets were not publicly disclosed and had been adequately protected. Life Spine, Inc. v. Aegis Spine, Inc., Case No. 21-1649 (7th Cir. Aug. 9, 2021) (St. Eve, J.)
The underlying conflict in this case has its roots in a short-lived business relationship between two companies specializing in selling spinal implant devices. Life Spine makes and sells a device called the ProLift Expandable Spacer System. Aegis Spine contracted with Life to distribute Life’s ProLift system to hospitals and surgeons for scheduled surgeries. Under the distribution agreement, Aegis was obligated to protect Life’s confidential information, act as a fiduciary for Life’s property and refrain from reverse engineering the ProLift system. Aegis did not abide by its contractual promises. It gave information about Life’s ProLift system to L&K Biomed, Aegis’s parent company and Life’s direct competitor. L&K used Life’s confidential information to develop a competing spinal implant device. Shortly after L&K’s device appeared on the market, Life sued Aegis for trade secret misappropriation and breach of the distribution agreement. The district court ruled in favor of Life, granting its motion for preliminary injunction against Aegis and its business partners, all of whom could no longer market the competing product. Aegis appealed.
Aegis argued that the injunction rested on the flawed legal conclusion that a company can have trade secret protection on a device that it publicly discloses through patents, displays and sales. The Seventh Circuit disagreed.
While the Court reaffirmed that there can be no trade secret protection in information available in the public domain, it found that such was not the nature of the information sought to be protected in this matter. Rather, the Seventh Circuit agreed with the district court that Life did not publicly disclose the specific information it sought to protect via patenting, displaying and selling its ProLift system.
The ProLift expandable spinal implant consists of the implant (or cage) component and an installer. The cage comprises an upper and lower endplate, a nose and base ramp and an expansion screw. The installer is used to insert the cage into a patient’s spine and expand the affected spinal disc height. Life considers “the precise dimension and measurements of the ProLift components and subcomponents and their interconnectivity” to be confidential trade secrets. The district court found that third parties are unable to access that precise dimensional information without first signing confidentiality agreements, and the information is not available in any of Life’s marketing materials (which include only dimensional approximations) or patents. Life’s ProLift system cannot be purchased by the general public or even handled at industry convention displays without Life’s close supervision. Instead, Life’s distributors sell ProLift directly to hospitals and surgeons for scheduled surgeries only.
The Seventh Circuit noted that “a limited disclosure” does not destroy all trade secret protection on a product, allowing a company to maintain trade secret protection on undisclosed “concrete secrets” of its product, even if the company has publicly disclosed other aspects of that same product. The Seventh Circuit explained that the same principle applies to public display or sales: Such activity does not result in forfeiture of trade secret protection unless the trade secret is “readily ascertainable” upon examination of the product. The Court stated that Aegis’s argument was critically flawed in treating trade secret protection “as an all‐or‐nothing proposition for a given product—either it exists, or it does not.” Since trade secret protection was sought for the specific dimensions and measurements of the ProLift product (rather than the product itself), the Court agreed that Life was only seeking to enforce a protectable trade secret.
In its appeal, Aegis relied on an 11th Circuit case, Roboserve v. Tom’s Foods (1991), where Roboserve lost trade secret protection on a vending machine by selling almost 1,300 machines to a company that resold them to distributors that had “no direct connection to Roboserve.” Unlike Life’s closely guarded ProLift system, “Roboserve’s vending machine was not secret because countless distributors had unlimited access to it.” In contrast, the trade secrets in issue here are only accessible to third parties who sign confidentiality agreements, the Seventh Circuit explained.
Aegis also argued that the district court “wrongly relied on a presumption of irreparable harm.” On that issue, the Seventh Circuit agreed that “the district court thought a presumption of irreparable harm attached upon a showing of likely success on a trade secret claim. And indeed, that used to be true in this circuit.” However, the Supreme Court of the United States rejected that presumption in its 2006 eBay v. MercExchange decision. The Seventh Circuit found that the erroneous application of the presumption of irreparable harm was harmless, because Life had presented evidence that it would lose market share and customers in absence of the preliminary injunction, and the district court found “some likelihood” of irreparable harm stemming from loss of goodwill and reputation, all of which was “sufficient to sustain the injunction” and did not warrant reversal.
Practice note: This case demonstrates the nuanced nature of trade secret protection and reminds practitioners and companies alike that just because something is patented, sold and displayed, it is not automatically devoid of trade secret protection.
